CLASSICAL HODGKIN LYMPHOMA
Clinical trials for CLASSICAL HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new CLASSICAL HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for CLASSICAL HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kids with lymphoma: drug combo may replace harsh chemo
Disease control Not yet recruitingThis study tests a combination of two drugs, camrelizumab and ivarmacitinib, as a first treatment for children aged 6-18 with newly diagnosed classical Hodgkin lymphoma. The goal is to see if this approach can achieve a complete metabolic response (no signs of active cancer) whil…
Matched conditions: CLASSICAL HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Engineered immune cells take on aggressive lymphomas in new trial
Disease control Not yet recruitingThis study tests a new treatment called CD70.CAR NK cells for people with diffuse large B-cell lymphoma or Hodgkin lymphoma that did not respond to or came back quickly after initial therapy. The treatment uses specially designed immune cells from a donor to find and attack cance…
Matched conditions: CLASSICAL HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Immune cell therapy trial offers new hope for young hodgkin lymphoma patients
Disease control Not yet recruitingThis early-stage trial tests a new treatment for children, adolescents, and young adults with a certain type of Hodgkin lymphoma that has come back after initial therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer…
Matched conditions: CLASSICAL HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: New York Medical College • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Promising new combo aims to tame hodgkin lymphoma in young patients
Disease control Not yet recruitingThis study tests whether adding nivolumab to standard chemotherapy (AVD) can better control early-stage Hodgkin lymphoma in patients aged 2 to 21. The treatment is given to 15 participants to see if it is safe and effective. The goal is to improve outcomes while reducing long-ter…
Matched conditions: CLASSICAL HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New CAR T-Cell combo trial targets tough hodgkin lymphoma in youth
Disease control Not yet recruitingThis trial tests whether giving CD30-targeting CAR T-cells after a strong chemotherapy and stem cell transplant is safe and feasible for children, teens, and young adults with poor-risk classical Hodgkin lymphoma. About 21 participants aged 6 to 29 will receive the treatment. The…
Matched conditions: CLASSICAL HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: New York Medical College • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC